EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 73 filers reported holding EDGEWISE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $81,192,069 | +10.8% | 4,508,166 | +12.2% | 0.00% | +100.0% |
| Q1 2024 | $73,277,978 | +215.2% | 4,017,433 | +89.0% | 0.00% | 0.0% |
| Q4 2023 | $23,251,657 | +96.6% | 2,125,380 | +3.0% | 0.00% | – |
| Q3 2023 | $11,829,132 | -24.9% | 2,064,421 | +1.6% | 0.00% | – |
| Q2 2023 | $15,747,682 | +17.7% | 2,031,959 | +1.3% | 0.00% | – |
| Q1 2023 | $13,378,853 | -24.5% | 2,005,825 | +1.2% | 0.00% | – |
| Q4 2022 | $17,728,056 | +2.8% | 1,983,004 | +13.2% | 0.00% | -100.0% |
| Q3 2022 | $17,239,000 | +76.6% | 1,751,845 | +42.8% | 0.00% | – |
| Q2 2022 | $9,763,000 | -16.9% | 1,226,568 | +1.3% | 0.00% | – |
| Q1 2022 | $11,748,000 | -35.9% | 1,211,093 | +1.0% | 0.00% | – |
| Q4 2021 | $18,326,000 | +87.9% | 1,199,400 | +104.1% | 0.00% | – |
| Q3 2021 | $9,753,000 | -21.5% | 587,521 | +0.8% | 0.00% | – |
| Q2 2021 | $12,432,000 | +218.8% | 582,863 | +385.7% | 0.00% | – |
| Q1 2021 | $3,900,000 | – | 120,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |